Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

Senseonics Holdings announced a $80 million underwritten public offering of 8 million shares at $5.00 per share and pre-funded warrants. The offering is expected to close on May 4, 2026. Net proceeds will fund the launch of Eversense 365 and development of pipeline products.

04/30/2026, 9:50 PM • GlobeNewswire

Middle East and Africa Continuous Glucose Monitoring Market Forecast and Company Analysis Report 2026-2034 Featuring Dexcom, Medtronic, Senseonics, Abbott Diabetes Care, and GlySens

The Middle East and Africa CGM market is projected to grow from USD 320.44 million in 2025 to USD 855.30 million by 2034 at an 11.53% CAGR, driven by rising diabetes prevalence, healthcare infrastructure improvements, and digital health integration. Key growth factors include government initiatives promoting preventive care and increasing smartphone adoption for remote monitoring, though high device costs and limited reimbursement remain barriers.

04/29/2026, 4:31 AM • GlobeNewswire

Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System

Senseonics launched its Eversense 365 continuous glucose monitoring system in Sweden with planned rollouts in Germany, Spain, and Italy. The implantable CGM doubles sensor lifespan to one year compared to its predecessor and reduces calibration frequency from daily to weekly. The company reported Q4 2025 revenue of $14.3 million, a 72% year-over-year increase, and announced integration with Sequel Med Tech's automated insulin delivery system.

04/24/2026, 7:00 AM • GlobeNewswire

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Health; Senseonics demonstrated strong real-world data for its year-long continuous glucose monitor; Microbot Medical achieved clinical milestones with its robotic endovascular system; LivaNova received FDA approval for its sleep apnea treatment device; and Clover Health showed AI-assisted primary care reduces hospitalizations in high-risk patients.

03/27/2026, 10:15 AM • Benzinga

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

Senseonics presented real-world evidence from 5,059 Eversense 365 CGM users showing sustained performance over a full year with 93.8% average transmitter wear time, mean GMI of 7.14%, and mean TIR of 66%. Over 75% of users achieved hypoglycemic targets. Early data from the twiist AID system combined with Eversense 365 showed even stronger results with mean GMI of 6.79% and TIR of 77%.

03/14/2026, 10:15 AM • GlobeNewswire

Senseonics Tumbles As Q3 Results And Split Hit Stock

Senseonics reported Q3 preliminary revenue of $8.1 million, a 91% year-over-year increase, but announced a 1-for-20 reverse stock split that reduced outstanding shares from 816 million to 41 million, causing stock price to drop.

10/07/2025, 1:17 PM • Benzinga